GNH USA

Europe — EMA

Minatuss (Butamirate Citrate)

GNH USA supplies Minatuss (Butamirate Citrate), a antitussive for dry and non‑productive coughs. Request a quote for global supply.

Request sourcing

1
Pack/s

What is Butamirate Citrate?

Butamirate citrate, the active ingredient in Minatuss, is an antitussive presented as an oral dosage form for oral use. It suppresses dry, non‑productive coughs in adults and adolescents and acts centrally to reduce the cough reflex without affecting mucus clearance.

GNH USA supplies Minatuss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

What is Butamirate Citrate used for?

Butamirate citrate is an antitussive that reduces the frequency of dry, non‑productive coughs.

- Dry cough: provides symptomatic relief by decreasing cough frequency. - Non‑productive cough: alleviates throat irritation without affecting mucus clearance. - Cough associated with upper respiratory tract infections: helps control coughing episodes while the underlying infection resolves.

What are the side effects of Butamirate Citrate?

Butamirate citrate may cause adverse reactions, which are generally mild but can be serious in rare cases.

Common Side Effects: - Nausea: mild stomach upset reported by some patients. - Dizziness: transient light‑headedness, especially after the first dose. - Drowsiness: occasional sleepiness, advise caution when driving. - Headache: mild to moderate headache in a minority of users. - Dry mouth: reduced salivation leading to throat discomfort.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, or angioedema requiring medical attention. - Severe dizziness or vertigo: may indicate central nervous system involvement. - Hallucinations or confusion: rare neuropsychiatric events. - Respiratory depression: extremely rare but serious, especially if combined with other depressants.

What precautions apply to Butamirate Citrate?

When prescribing or dispensing butamirate citrate, consider the following precautions.

- Assess hypersensitivity: avoid use in patients with known allergy to butamirate citrate. - Hepatic impairment: use with caution and monitor liver function. - Concomitant CNS depressants: avoid or adjust dose if combined with other sedatives. - Excessive sedation: monitor patients for profound drowsiness or impaired coordination. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

What does Butamirate Citrate interact with?

Butamirate citrate can interact with other medicines; awareness of the interaction level helps manage risk.

Major Interactions (Avoid): - Other centrally acting cough suppressants: may lead to excessive suppression of the cough reflex. - Monoamine oxidase inhibitors (MAOIs): risk of heightened central nervous system effects.

Moderate Interactions (Monitor Closely): - Alcohol: can increase drowsiness and dizziness. - Sedating antihistamines: may enhance sedation. - Opioid analgesics: additive central depressant effects. - Benzodiazepines: potential for increased sedation and respiratory depression.

Frequently asked questions

What is Minatuss used for?+
Minatuss contains butamirate citrate and is indicated for the symptomatic relief of dry, non‑productive coughs. It helps reduce the frequency and intensity of coughing episodes without affecting mucus production, making it suitable for adults and adolescents experiencing irritating coughs.
How does butamirate citrate work?+
Butamirate citrate acts on the medullary cough centre in the brainstem, raising the threshold required to trigger a cough. By modulating neuronal activity centrally, it suppresses the cough reflex while preserving normal airway clearance, which is why it is effective for dry coughs.
What is the usual dose of Minatuss?+
The specific dose of Minatuss is determined by the prescribing healthcare professional based on the patient’s age, weight, and clinical condition. Patients should follow the prescriber’s instructions and the product label; no universal dosing regimen is provided here.
Is Minatuss safe during pregnancy or breastfeeding?+
Safety data for butamirate citrate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.
How do I order Minatuss from GNH USA?+
To place an order, submit an enquiry on the Minatuss product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does Minatuss compare with other cough suppressants?+
Butamirate citrate differs from dextromethorphan, another common antitussive, by acting primarily on the medullary cough centre rather than NMDA receptors. Clinical experience suggests comparable efficacy for dry cough, but individual response and side‑effect profiles may vary, so choice depends on patient tolerance and physician preference.
What are the storage and handling requirements for Minatuss?+
Minatuss should be stored at ambient temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.
How is Minatuss administered?+
Minatuss is taken orally, usually with a glass of water. The tablet (or oral formulation) should be swallowed whole unless otherwise directed by a healthcare professional. It can be taken with or without food, but patients should follow the prescriber’s specific instructions.
What are the most serious risks associated with Minatuss?+
Serious, though rare, risks include allergic reactions such as rash, angioedema, or severe dizziness, and in extremely uncommon cases, hallucinations or respiratory depression. Patients should seek immediate medical attention if they experience any signs of an allergic response or unexpected neurological symptoms.
Who should not use Minatuss?+
Minatuss should be avoided in individuals with known hypersensitivity to butamirate citrate or any excipients in the formulation. Caution is also advised for patients with severe hepatic impairment, and it should not be combined with other central cough suppressants or MAO inhibitors without medical supervision.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Product details

Drug
Butamirate Citrate
Route
Oral Use
Manufacturer
Galenica Sa
Origin
EU

Related products